Purpose: Both granular and lattice deposits are present in Avellino corneal dystrophy (ACD), primarily associated with the R124H mutation of transforming growth factor-b-induced (TGFBIp). We investigated the presence of these deposits in other TGFBI mutations and the use of Thioflavin-T (ThT), a fluorescent amyloid stain for characterizing corneal amyloid deposits.
C orneal epithelial and stromal dystrophies linked to the transforming growth factor b induced (TGFBI) gene on human chromosome 5q31 have thus far been classified according to their phenotypes. 1, 2 Avellino corneal dystrophy (ACD) manifests both granular and lattice deposits, for which reason it is also referred to as ''combined granular-lattice corneal dystrophy.' ' 3 In 1988, Folberg et al 4 reported the histopathological findings of patients with this corneal dystrophy and traced the family origins of each patient to the Italian province of Avellino, from which the dystrophy gets its name. However, the subtle differences in clinical presentation of ACD and granular corneal dystrophy (GCD) were described long before ACD was linked to Avellino. In 1938, Bucklers described the phenotype of ACD, and using the same cases, Weidle 5 subcategorized GCD based on these differences. 1 The fact that ACD was known as a milder form of GCD for many decades provides the historic reason that ACD is subclassified today under GCDs as GCD type II. Histochemically, ACD is characterized by both hyaline and amyloid deposits, features of granular and lattice corneal dystrophies, respectively. Hyaline and amyloid materials can be detected histochemically by using trichrome and Congo red staining, respectively. Other than Congo red, amyloid materials also stain with fluorescent dye Thioflavin-T (ThT). 6 A G!A mutation at nucleotide 418 in the TGFBI gene leading to an arginine to histidine substitution at codon 124 (R124H) has been correlated with the phenotype of ACD. [7] [8] [9] [10] [11] [12] [13] Patients with homozygous mutations show more severity in phenotype compared with those with heterozygous mutations. 14 ACD has frequently been misdiagnosed clinically as GCD I, which is usually associated with TGFBIp R555W mutation. 11, 15, 16 This is probably because of the late onset of lattice deposits in ACD cases and unfamiliarity with icicleand star-shaped opacities, characteristic of ACD, when lattice lines may not be obvious. 17, 18 For this reason, many investigators think that direct examination may be insufficient for the definite diagnosis of ACD and that mutation analysis confirming the R124H TGFBIp mutation should be required. 9, 19, 20 However, there have been reported cases of patients having a clinicopathological diagnosis of ACD but having the TGFBIp R555W mutation. 20, 21 The current work describes 3 unrelated cases that were clinically and histopathologically diagnosed as ACD with the R124C TGFBIp mutation, which is typically associated with lattice corneal dystrophy (LCD).
MATERIALS AND METHODS

Clinical Specimens
Corneal specimens were obtained after therapeutic keratoplasty from 3 patients (1 eye each) with a clinical diagnosis of ACD. The retrospective review was approved by Institutional Review Boards of Washington University and Eye Hospital of Ho Chi Minh City, Vietnam, respectively. Deep anterior lamellar keratoplasty (DALK) was performed in 1 male patient (42 years) at Washington University (case 1), and penetrating keratoplasty was performed at Eye Hospital of Ho Chi Minh City, Vietnam, in 2 unrelated male patients (27 and 35 years, respectively) (cases 2 and 3). No known history of hereditary corneal diseases was noted in the immediate family members of these patients. However, the only son (15 years) of the patient from Washington University has been known to have symptoms of recurrent corneal erosions without evident corneal opacity. All 3 patients had no history of ocular surgery before keratoplasty and had severe symptoms of recurrent corneal erosion and severe decrease of vision in both eyes with dense central granular corneal opacities. The corneal buttons thus obtained from keratoplasty were fixed in 10% buffered formalin. Blood samples were collected from these 3 patients for genetic analysis after informed consents. Histopathologic studies of all corneal specimens were performed at Washington University. Histological sections of normal corneas and 3 previously identified and unrelated cases of LCD (man: 79 years, woman: 84 years, and woman: 81 years) from Washington University were used as negative and positive controls, respectively, for ThT fluorescence microscopy. One of the 3 LCD control cases manifested recurrent LCD (woman: 84 years). Normal corneal tissues for sections and protein extraction were obtained from Mid-America Transplantation Services (Saint Louis, MO).
Materials
Precision Plus Protein WesternC standards molecular weight protein markers, 7.5% tris-HCl precast gels, 0.2-mm PVDF blotting paper, and StrepTactin-horseradish peroxidase conjugate were purchased from Bio-Rad Laboratories, Inc. (Hercules, CA). Affinity-purified rabbit anti-TGFBI antibody was obtained from Proteintech Group (Chicago, IL). Recombinant full-length TGFBI and monoclonal anti-TGFBI antibodies were purchased from R & D Systems (Minneapolis, MN). ECL horseradish peroxidase-linked donkey anti-rabbit IgG antibody and ECL Plus western blotting detection system were purchased from GE Amersham (Piscataway, NJ). SYTOX Orange nucleic acid fluorescent stain, Alexa633conjugated goat anti-rabbit secondary antibody, Image-iT FX signal enhancer, and ProLong Gold antifade reagent were obtained from Invitrogen (Carlsbad, CA). Antigen unmasking solution for antigen retrieval was purchased from Vector Laboratories (Burlingame, CA). Phenylmethyl sulfonyl fluoride was purchased from Amresco (Solon, OH). Puromycin was purchased from Clonetech (Mountain View, CA), and FuGENE 6 transfecting agent was obtained from Roche Applied Sciences (Indianapolis, IN). HEK293FT cells and all other cell culture reagents were obtained from Invitrogen. HisPur Cobalt resin was obtained from Pierce (Rockford, IL). Citrisolv solvent and clearing agent for histology, ThT, tris base, urea, and bromophenol blue were obtained from Fisher Scientific (Pittsburgh, PA). Sodium dodecyl sulphate (SDS), b-mercaptoethanol, glycine, glycerol, and all other chemicals were purchased from Sigma Aldrich (Saint Louis, MO).
Purification of Recombinant TGFBIp
The human TGFBI complementary DNA was amplified using polymerase chain reaction from an I.M.A.G.E. clone (clone ID 2957915, Genbank accession number BE206112) and inserted into pIRESpuro2 for stable expression in HEK293FT mammalian cells. A hexahistidine tag and a Strep II tag were inserted after the signal peptide and before the arginine-glycine-aspartate (RGD) motifs of TGFBIp, respectively. Cells were transfected using FuGENE 6 transfecting reagent, after which they were maintained in Dulbecco's modified Eagle medium (DMEM) (10% fetal bovine serum [FBS] and 3 mg/mL puromycin). Individual clones were selected by monitoring TGFBI expression levels measured by dot-blot assays. Clones stably expressing TGFBIp were cultured in Dulbecco's modified Eagle medium (DMEM) (10% FBS, 3 mg/mL puromycin). For purification of TGFBIp, medium was slowly replaced with serum-free FreeStyle293 media over the course of 3 passages. Secreted TGFBIp (amino acids 24-641) was purified by metal affinity chromatography using HisPur Cobalt resin, after which it was dialyzed against phosphate buffer and concentrated by filtration (50-kDa centrifuge filters) to lyophilize and store at 280°C until needed. Lyophilized TGFBIp was dissolved in 10 M urea (10 mM phosphate buffer, pH 7.4) for 1 hour at room temperature and then gel-filtered into phosphate buffer. It was then allowed to aggregate in phosphate-buffered saline (PBS) at 37°C.
Western Blotting
Normal corneal buttons were homogenized in protein lysis buffer as previously described. 22 In brief, half a normal corneal button stored in liquid nitrogen was homogenized on ice, after which 200 mL of lysis buffer A (100 mM glycine; 5.5 mM tris, pH 8.2; 2.7% SDS; 3.45 M urea; 12% b-mercaptoethanol; and 0.014% bromophenol blue) or B (1% SDS, 10% glycerol, 1% b-mercaptoethanol, and 0.001% bromophenol blue) was added to it. After addition of protease inhibitor, phenylmethyl sulfonyl fluoride, mixtures were homogenized again and kept at room temperature for 1 hour. The mixture was then centrifuged at 16000g for 5 minutes. The supernatants were stored at 220°C until used as the protein lysis samples. Proteins were separated on an SDS-polyacrylamide gel by electrophoresis and transferred onto polyvinylidene fluoride (PVDF) membranes. Recombinant TGFBIp (amino acids 24-641) purified from transfected HEK293FT cells and full-length recombinant TGFBIp (amino acids 1-683) purchased from R & D systems were used as controls on the same gel. Membranes were blocked with 5% nonfat dry milk in tris-buffered saline-Tween and then incubated with TGFBIp antibody (1:200 dilution) overnight at 4°C. Three TGFBIp antibodies (R & D Systems, Proteintech Group, and 1 rabbit anti-TGFBIp custom made for our laboratory) were used on separate blots. Blots were washed with tris-buffered saline-Tween and probed with donkey anti-rabbit horseradishconjugated secondary antibody (1:1,00,000 dilution) for 1 hour at room temperature. Western C molecular weight protein markers were developed using StrepTactin-horseradish peroxidase conjugate, separately from the lanes containing TGFBIp samples. Blots were developed using electrochemifluorescence ECL reagent and imaged using the STORM PhosphorImager system (GE Amersham) with a 450-nm excitation and 520LP emission filter. Resultant images from the scanner control software were analyzed using NIH ImageJ software.
Immunofluorescence and Histological Staining
Normal and dystrophic corneas were fixed in 10% buffered formalin at room temperature, dehydrated in ethanol, and embedded in paraffin. For immunofluorescence, 4-mm sections were deparaffinized by incubation in Citrisolv for 10 minutes and subsequently rehydrated using a series of aqueous ethanol solutions (100%-30% vol/vol). After washing with PBS (pH 7.4), antigen retrieval was carried out using citrate buffer-based Antigen Unmasking solution (pH 6.0). Tissue sections were then blocked using Image-iT FX signal enhancer for 30-50 minutes at room temperature and incubated with TGFBIp antibody (1:200 in PBS, antibody from Proteintech Group) overnight at 4°C. Two other antibodies specific for TGFBIp were used for immunofluorescence staining of dystrophic and nondystrophic cornea sections. One of them was monoclonal mouse antibody (R & D Systems), and the other was a polyclonal affinity-purified rabbit antibody (purified in-house). After fixation with 0.4% paraformaldehyde for 15 minutes, goat anti-rabbit Alexa 633 secondary antibody (1:500) and SYTOX Orange nuclear stain (1:1000) were applied for 1 hour at room temperature. Tissue sections refixed with 0.4% paraformaldehyde were then incubated in 200 mM ThT solution for 1 hour and mounted using ProLong Gold antifade reagent. Three days after mounting, slides were sealed using nail polish and viewed using a Zeiss LSM 510 confocal microscope (Carl Zeiss Microimaging, Thornwood, NY) and a 320 objective lens. The 458-, 543-, and 633-nm lasers were used to excite ThT, SYTOX Orange, and Alexa 633 secondary antibody, respectively. The resultant fluorescence was detected under multitrack mode using 475-nm, 525-nm, 560-nm, 615-nm, and LP650 emission filters, respectively. Paraffin sections of 5 mm from dystrophic and normal corneas were also stained routinely with Masson trichrome and/or Congo red stain and imaged using an Olympus BX60 microscope (Olympus, Japan) and a RT Slider Spot camera.
Genotyping
The genotyping of our 3 index cases was conducted by the John and Marcia Carver Nonprofit Genetic Testing Laboratory at the University of Iowa.
RESULTS
Genotyping
Automated DNA sequencing of the coding sequence of the TGFBI gene from cases 1, 2, and 3 revealed the following disease-causing variation and other nondisease-causing variations. 
Clinical and Histopathological Findings
Slit-lamp examination of all index cases showed bilateral central corneal opacity with snowflake-like or crumb-like granular deposits (arrows in Fig. 1A , case 1) and lattice-line or arborizing deposits in both eyes (asterisks in Fig. 1A , case 1), supporting a clinical diagnosis of ACD. Masson trichrome staining of all the index tissue sections showed trichrome-stained hyaline aggregates in the anterior stroma, confirming presence of granular deposits (red-colored deposits, Fig. 1B , case 2). Also present were multiple subepithelial deposits ( Fig. 1B , arrows) and fusiform stromal lesions in the mid-to-deep stroma (Fig. 1B, arrowheads) , neither of which stained with trichrome. When these sub-Bowman trichrome-stained deposits are present underneath the subepithelial deposits, they are found to be larger compared with those located under normal epithelium or in deeper stroma. Congo red staining of tissue sections showed presence of amyloid deposits under normal and polarized light (Figs. 1C, D; case 2). The fusiform deposits in the mid-to-deep stroma stained with Congo red and showed characteristic yellow-green birefringence under polarized light (arrowheads), indicating that these are amyloid in nature, as found in LCD. There are also some Congo red-stained birefringent deposits in the sub-Bowman or anterior stroma (underneath the subepithelial deposits). Interestingly, the subepithelial deposits (arrows in Figs. 1B, D) did not stain with Congo red. Tissue sections from cases 1 and 3 also showed similar Congo red staining patterns (data not shown). Approximately 1 year after DALK in case 1, recurrent granular deposits were noted in the corneal graft slightly off the visual axis (Fig. 1E) with a best-corrected visual acuity of 20/25. Taken together, the clinical findings of granular and lattice-like deposits by slitlamp examination and presence of both trichrome-stained hyaline material and Congo red-stained amyloid material in tissue sections in all our index cases support the diagnosis of ACD clinically and histopathologically.
Specificity of TGFBIp Antibody
Although the TGFBIp antibody obtained from Proteintech Group has been shown to be specific in staining of cell lysates and lung tissue sections, 23 to establish its specificity for corneal TGFBIp, crude protein extracts from the cornea were separated by SDS electrophoresis and probed with this antibody. The immunoblot in Figure 2 
Amyloid and Nonamyloid Deposits of TGFBIp
To establish if the observed amyloid deposits in corneal tissue consist of TGFBIp, tissue sections were immunofluorescently costained with TGFBI antibody and amyloid-specific fluorescent probe ThT. A representative image of a cornea section from case 2 stained with TGFBIp antibody (in green), ThT (in red), and nuclear stain SYTOX Orange (in blue) is shown in Figure 3 . Interestingly, the subepithelial deposits that stained with neither trichrome nor Congo red in histopathological sections (Fig. 1, arrows) stained positively with TGFBIp antibody (as seen, in green, in Fig. 3A and Fig. 3C , arrows), but not with ThT. A dense band of amyloid deposits (stained with ThT in red, in Figs. 3B, C) were noted in the anterior stroma just beneath the subepithelial deposits. Although TGFBIp was present throughout the entire stroma, focal areas of TGFBIp aggregates with higher fluorescent intensity can be observed (Figs. 3A-C, arrowheads). These aggregates correspond to the fusiform deposits in Fig. 1 , which also stained positively with ThT, indicating that they contain TGFBIp and are amyloid in nature. It is evident from Figure 3C that the subepithelial deposits consist of TGFBIp and are nonamyloid in nature. In contrast, the deposits in the anterior stroma and smaller fusiform lesions (arrowheads) in the mid-todeep stroma contain TGFBIp and are amyloid in nature. Furthermore, these ThT-stained deep stromal deposits were dichroic and birefringent by Congo red staining under polarized light (Figs. 1C, D) , corroborating that they are indeed amyloid in nature.
Similar 3-color florescence composite images of dystrophic tissue from cases 1 and 3 are shown in Figures 4A and B , respectively. Although there is thin epithelium secondary to recurrent erosions in the tissue from case 1, it is evident in Figures 4A and B that the TGFBIp deposits in the anterior stroma are amyloid in nature. The smaller and deeper fusiform lesions are also ThT-stained in tissue sections from cases 1 and 3 (Figs. 4A, B ), similar to those in case 2. Moreover, none of the subepithelial TGFBIp deposits observed in these 3 cases of ACD were amyloid in nature (Figs. 3C, 4A, B; arrows) . We used cornea tissue sections from patients with LCD as positive controls for ThT staining (Fig. 4C) . These sections exhibited similar staining patterns as in those from our patients with ACD with positive ThT staining in both anterior and deeper stroma, except that no subepithelial TGFBIp deposits were observed in LCD tissues. No focal TGFBIp deposits or ThT staining was observed in normal tissues (Fig. 4D ). However, we also observed TGFBIp staining in the interlamellar junctions of the stroma in normal tissue, as previously described by Streeten et al. 24 
DISCUSSION
In 1938, Bucklers described a family of patients who suffered from what we now refer to as ACD, a milder version of GCD. These cases were used 50 years later by Weidle 5 to subclassify variants of GCD. 1 In 1988, Folberg et al described a series of 4 unrelated patients with ACD as atypical GCD with pathologic features of lattice-like amyloid deposits. The anterior stroma was reported to contain granular deposits amongst which amyloid matter was also shown to be present by Congo red staining. In addition to these amyloid deposits located in the superficial stroma, amyloid was also noted in the mid-to-deep stromal fusiform lesions. 4 These findings have been confirmed by many other investigators. 3, 8, 11, 15, 24 Thus, ACD can be histopathologically defined as having both trichrome-stained hyaline deposits (corresponding to granular deposits) and Congo red-stained or ThT-stained amyloid deposits (corresponding to lattice deposits). Classic clinical signs of ACD include anterior stromal discrete grayish-white deposits, lattice lesions in the mid-to-posterior stroma, and anterior stromal haze. 25 Using these definitions of ACD, it is clear that the index cases of corneal dystrophy described in this study should be clinically and histopathologically categorized as ACD. However, to our surprise, all 3 of our index cases showed R124C TGFBIp mutation, which is usually associated with LCD.
The corneal dystrophy described in this study also show similar TGFBIp antibody-staining characteristics as those observed by other investigators. Using TGFBIp antibodies raised against amino acids 426-682 (K15) and 69-364 (K2), Konishi et al 26 have shown ACD corneas with R124H TGFBIp mutation to have subepithelial TGFBIp deposits (trichrome stained), superficial stromal TGFBIp deposits (trichrome stained), and fusiform TGFBIp deposits in the mid-to-deep stroma (Congo red stained). The major difference between their cases with ACD and our series is that the subepithelial deposits observed in our study did not stain with trichrome or Congo red. In addition, there was amyloid deposition in the anterior stroma (by Congo red and ThT staining) amongst trichrome-stained deposits in our tissues. The granular deposits of ACD are frequently described to break through Bowman membrane and extend into the corneal surface. 18, 24, 27 Konishi et al showed that tissues from patients with GCD with R555W mutation had only such trichrome-stained subepithelial deposits. Interestingly, tissues from 5 of their 7 patients with LCD with R124C mutation showed trichrome-stained deposits between the epithelium and Bowman layer. However, those subepithelial deposits did not with Congo red. To the best of our knowledge, our report is the first one of R124Crelated corneal dystrophy tissue to contain subepithelial TGFBIp deposits that do not stain with trichrome along with trichrome-stained deposits in the anterior stroma. In fact, these subepithelial deposits do not contain amyloid either, as indicated by lack of Congo red birefringence under polarized light or ThT fluorescence. Such subepithelial deposits that stain with neither trichrome nor Congo red or ThT were observed in a patient with the H626P TGFBIp mutation, 28 suggesting that this phenomenon of nonhyaline and nonamyloid subepithelial aggregation of TGFBIp is not limited to the R124C TGFBIp mutation, as shown in our index cases. Precisely, Wheeldon et al described the H626P TGFBIp mutation-carrying patient to have phenotypic features of both type I and type II corneal dystrophies of the Bowman layer, also known as Reis-Buckler and Thiel-Behnke (or honeycomb) corneal dystrophies, respectively. In fact, it has been shown that such undulating subepithelial deposits that do not stain with either Congo red or trichrome but do contain TGFBIp are a classical feature of Thiel-Behnke corneal dystrophy, which is associated with R555Q TGFBIp mutation. 24, 29, 30 This fibrocellular layer that replaces the Bowman layer is shown to consist of curly fibers by transmission electron microcopy. Because there were no tissue specimens from our index cases remaining for transmission electron microscopic processing, we are unable to confirm that the subepithelial deposits observed in the cases described herein have the same ultrastructure as those present in Thiel-Behnke corneal dystrophy tissues. However, because no amyloid deposits are associated with Thiel-Behnke corneal dystrophy, our index cases would most appropriately be classified as a variant form of ACD, one that manifests amyloid and hyaline deposits, as in classical ACD, but it also shows TGFBIp nonamyloid and nonhyaline subepithelial deposits, as those found in Thiel-Behnke corneal dystrophy. It is possible that these subepithelial deposits are likely a result of hyperproductivity of TGFBIp in hyperproliferating epithelial cells.
After Vassar and Culling 6 demonstrated the use of ThT to identify amyloid deposits in various organs such as the kidney in 1959, ThT had been used to identify amyloid deposits in the cornea using UV filters in the late 1960s. 27, 31, 32 It was pointed out that amyloid deposits are more sharply defined with ThT staining compared with other amyloid dyes such as Congo red, although the technique did not become widely adapted in routine histopathology, probably because of photobleaching and the limited availability of fluorescent microscopes at the time. 6, 33 With the advent of fluorescence antiphotobleaching agents, the means to take and store digital images, and the availability of fluorescence microscopes, these initial disadvantages of ThT are largely resolved. We have imaged ThT-stained cornea sections up to several months after staining without problems of fluorescence photobleaching. In a recent study in which both ThT and Congo red were used to detect amyloid deposits in corneal dystrophies, Congo red stained the stroma but was not birefringent under polarized light. 34 Such a finding suggests that although Congo red bound to the material, it was not amyloid in nature because of the lack of Congo red molecule alignment, which is responsible for the birefringent property of the dye. The ThT signal was negative because it is a fluorescent dye that has a high Stokes shift when bound only to amyloid, making it an ideal fluorescent reporter for amyloid. Although ThT fluorescence has been shown to depend on the morphology of amyloid fibrils, 35 it is not yet known to bind to native and partially folded conformations other than amyloid fibrils, as does Congo red. 36 According to the International Committee for Classification of Corneal Dystrophies (IC3D), corneal dystrophies have been categorized based on genetic, clinical, and histopathological findings, including the shape, distribution, and localization of deposits within the cornea. 1 Moreover, TGFBIp-related corneal dystrophies have been correlated with specific gene mutations. 37 The phenotype of ACD (GCD II) has been shown to correlate with the TGFBIp mutation R124H [7] [8] [9] [10] [11] [12] [13] 19 and can be distinguished as either homozygous or heterozygous. 14 Homozygous ACD has been further classified phenotypically as type I or type II depending on whether the anterior stromal opacity is spot-like or reticular. 38 However, there have been reports of cases that manifest the phenotype of ACD but have other mutations of TGFBIp other than R124H. 20, 21 A D123H TGFBIp mutation has been associated with ACD in Vietnamese patients. 7 Solari et al 21 described a Brazilian patient diagnosed with ACD but carrying the R555W TGFBIp mutation. Kocak-Altintas et al 20 investigated a Turkish family whose members were affected by corneal dystrophy, describing the corneal deposits to be similar to those in GCD. They pointed out that with increased age, ''lattice-type phenotype with fine, subtle, and linear or branching deposits were also observed.'' The genotype of 1 such elderly family member was found to carry the R555W TGFBIp mutation. In both reports, the authors assumed misdiagnosis because the patients did not have the R124H TGFBIp mutation, which is classically associated with ACD. However, it is possible that these cases, showing clear lattice lines in the cornea, are in fact a variant of ACD stemming from a non-R124H TGFBIp mutation, as in the cases described herein. Furthermore, before genotyping to search for TGFBIp mutations was routine practice, or that it was known that TGFBIp was a component of deposits in what we now refer to as TGFBIp-related corneal dystrophies, there have been reports of amyloid deposits in tissue from what seemed to be cases of GCD. 27, 31, [39] [40] [41] [42] We can assume that these cases were probably those of ACD misdiagnosed as GCD. However, in the pregenotyping era, investigators have also reported trichromepositive deposits in otherwise typical cases of LCD I. 16, 43, 44 Taken together, these observations suggest that abnormal TGFBIp protein has, in most cases, some tendency toward amyloid aggregation. This notion is consistent with our previous in vitro findings and those of others that native and mutant TGFBIp can all form amyloid aggregates. 45, 46 Data in the current study further support the idea that TGFBIp may also have an intrinsic tendency to form hyaline aggregates under certain circumstances.
In summary, this study demonstrates the potential use of ThT in costaining with immunofluorescence to detect amyloid deposits of TGFBIp. We have also confirmed that granular and lattice deposits can be associated with R124C TGFBIp mutation and shown that corneal tissues from such patients contain subepithelial TGFBIp deposits that are neither hyaline nor amyloid in nature, an additional feature that might substantiate that such cases be categorized as a variant form of ACD. As we work towards understanding the etiology and molecular mechanisms of corneal dystrophies related to TGFBI mutations, we have made progress in correlating genotype with phenotype. 1, 2 It has been proposed that the classification of TGFBIp-related corneal dystrophies be based on the mutation alone. 47, 48 Our study, however, demonstrates that a single TGFBIp mutation such as R124C can lead to multiple phenotypes, some of which may be generally correlated with other mutations such as R124H previously.
